Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 study of vadadustat for the treatment of anemia in late-stage CKD patients

Next Previous
Trial Profile

A Phase 3 study of vadadustat for the treatment of anemia in late-stage CKD patients

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vadadustat (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms VALOR

Most Recent Events

  • 07 Aug 2025 According to a Akebia Therapeutics media release, company is working towards its goal to initiate VALOR, a Phase 3 clinical trial to study the use of vadadustat for treating anemia in late-stage CKD patients who are not on dialysis by the end of this year. The company has requested a Type-C meeting with the U.S. Food and Drug Administration.
  • 13 Mar 2025 According to a Akebia Therapeutics media release, expect to initiate the VALOR study in the second half of this year.
  • 20 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top